Cue Biopharma, Inc.
CUE
NASDAQ·Healthcare·Biotechnology·Mkt cap $72.1M
$27.44
▼ -0.83%
P/E
-1.02
Mkt Cap
$72.1M
52-Wk Range
$4.98–$45.50
52-Week Range
$4.98 - $45.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 17.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Immuno-STAT fusion protein technology platform
- Strategic collaborations with pharmaceutical leaders (Merck, LG Chem)
- Differentiated approach to antigen-specific T cell activation
- Broad pipeline addressing multiple high-value therapeutic areas
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Revenue decline expected
Clinical trial advancement and regulatory milestones for lead candidates
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-5.6% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying CUE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 14, 2026
Reported EPS of -$24.14 vs -$1.69 consensus (-1328.4% surprise). Revenue of $7.9M vs $3.0M expected (+162.6%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1328.4%
Revenue trend · last 8Q
—
—
-75%
+11%
-36%
+1292%
+1251%
+167%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.3M
$1.6M
$421.0K
$3.0M
$2.1M
$21.9M
$5.7M
$7.9M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-1943.2%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CUE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related